• Sign the informed consent form voluntarily and follow the protocol requirements;

• Age ≥18 years old;

• Expected survival time ≥3 months;

• Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;

• Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;

• Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;

• At least one measurable lesion meeting the RECIST v1.1 definition was required;

• ECOG 0 or 1;

• The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

⁃ No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

⁃ The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;

⁃ Urinary protein ≤2+ or \< 1000mg/24h;

⁃ For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.